Leslie Citrome

New York Medical College — United States

Medicine · Health Sciences

74h-index21.7kcitations720works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(395), Bipolar Disorder and Treatment(162), Treatment of Major Depression(92), Health Systems, Economic Evaluations, Quality of Life(68), Mental Health and Psychiatry(65)

Publications716 total

What’s in a name? What shall we call xanomeline-trospium combination?
Expert Opinion on Drug Safety·2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them
American Journal of Psychiatry·2025· 3 cited
Mosaic Turner Syndrome and Treatment-Resistant Schizophrenia
The Primary Care Companion For CNS Disorders·2025
The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment
Neurology and Therapy·2025· 2 citedOpen Access
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia
Expert Opinion on Drug Metabolism & Toxicology·2025
Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
Neuropsychiatric Disease and Treatment·2025Open Access
28. BREXPIPRAZOLE FOR AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE: NUMBER NEEDED TO TREAT, NUMBER NEEDED TO HARM, AND LIKELIHOOD TO BE HELPED OR HARMED
American Journal of Geriatric Psychiatry·2025
Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis
Translational Psychiatry·2025· 9 citedOpen Access
Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial
The Lancet Psychiatry·2025· 1 cited
What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?
The Journal of Clinical Psychiatry·2025· 3 cited
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial
Neuropsychiatric Disease and Treatment·2025Open Access
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
Journal of Clinical Psychopharmacology·2025· 15 citedOpen Access
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
Journal of Clinical Psychopharmacology·2025· 17 citedOpen Access
Effect Sizes of Once-daily Valbenazine for Tardive Dyskinesia: A Post-hoc Analysis of KINECT® 3 Data (P10-5.017)
Neurology·2025
Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
Neuropsychiatric Disease and Treatment·2025· 4 citedOpen Access
A new paliperidone palmitate formulation: how is it different and where does it fit in our array of choices for long-acting formulations of risperidone and paliperidone?
Current Medical Research and Opinion·2025· 2 cited
A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males
The Journal of Clinical Psychiatry·2025
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Schizophrenia·2025· 1 citedOpen Access
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment·2025· 3 citedOpen Access
Understanding the Tolerability Profile of Xanomeline-Trospium Combination for the Treatment of Schizophrenia
The Journal of Clinical Psychiatry·2025· 2 citedOpen Access
page 1 of 36Next →

Frequent Co-authors

Jan Volavka(15), Pál Czobor(11), Jean-Pierre Lindenmayer(10), Joseph P. McEvoy(10), Thomas B. Cooper(9), Jeffrey A. Lieberman(9), Brian Sheitman(8), Miranda Chakos(6), Bruce J. Kinon(3), John M. Kane(3), Christoph U. Correll(3), Herbert Y. Meltzer(2), Robert M. Bilder(2), Robert Goldman(2), Matthew J. Hoptman(2), Michal Kunz(2), Lise Baltzer(2), Daniel Bridges(2), Karen A. Nolan(2), Kristen M. Ward(2)